Motesanib diphosphate (AMG 706), an oral angiogenesis inhibitor, demonstrates clinical efficacy in advanced thymoma

Authors

  • Arun Azad Department of Medical Oncology, Austin Health, Heidelberg, Victoria, Australia
  • Rebecca A. Herbertson Austin Health, Ludwig Institute for Cancer Research, Heidelberg, Victoria, Australia
  • David Pook Austin Health, Ludwig Institute for Cancer Research, Heidelberg, Victoria, Australia
  • Shane White Department of Medical Oncology, Austin Health, Heidelberg, Victoria, Australia
  • Paul L. R. Mitchell Department of Medical Oncology, Austin Health, Heidelberg, Victoria, Australia
  • Niall C. Tebbutt Department of Medical Oncology, Austin Health, Heidelberg, Victoria, Australia; Austin Health, Ludwig Institute for Cancer Research, Heidelberg, Victoria, Australia

DOI:

https://doi.org/10.1080/02841860802495362

Abstract

No abstract available

Downloads

Download data is not yet available.

Downloads

Published

2009-01-01

How to Cite

Azad, A., Herbertson, R. A., Pook, D., White, S., Mitchell, P. L. R., & Tebbutt, N. C. (2009). Motesanib diphosphate (AMG 706), an oral angiogenesis inhibitor, demonstrates clinical efficacy in advanced thymoma. Acta Oncologica, 48(4), 619–621. https://doi.org/10.1080/02841860802495362

Issue

Vol. 48 No. 4 (2009): Acta Oncologica

Section

Articles